HCW Biologics Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
HCWB$0.95-6.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity
| Stockholders’ Equity | |||||
|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balance, December 31, 2021 | 35,768,264 | $3,577 | 81,827,006 | $(30,637,343) | $51,193,240 |
| Issuance of Common Stock upon exercise of stock options | 108,176 | 11 | 15,767 | — | 15,778 |
| Stock-based compensation | — | — | 1,120,191 | — | 1,120,191 |
| Net loss | — | — | — | (14,900,703) | (14,900,703) |
| Balance, December 31, 2022 | 35,876,440 | $3,588 | $82,962,964 | $(45,538,046) | $37,428,506 |
| Issuance of Common Stock upon exercise of stock options | 148,664 | 15 | 23,724 | — | 23,739 |
| Stock-based compensation | — | — | 1,003,749 | — | 1,003,749 |
| Net loss | — | — | — | (24,994,277) | (24,994,277) |
| Balance, December 31, 2023 | 36,025,104 | $3,603 | $83,990,437 | $(70,532,323) | $13,461,717 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.